Metabolic fate of amino acids derived from muscular protein breakdown in septic patients

• Conditions: Muscle wasting; Protein breakdown; 10037008; 10004018; 10028393

• Registration Number: NL-OMON50749
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 21

Inclusion Criteria

1) Age >18 <75
2) Sepsis on admission (as defined by the Sepsis-3 criteria*)
3) Sepsis still persistent but stabilized as defined by continued need of
vasopressive drugs
- norepinephrine dose, > 0.05-0.25 ug/kg/min
4) Receiving enteral or parenteral nutrition
5) Intubated and Mechanically ventilated
- PaO2/FiO2 ratio of >100 and <300;
6) Femoral venous catheter in place OR eligible for femoral CVL placement
7) Arterial and peripheral venous line (any location) in situ
8) Expected ICU stay > 48 hours, * Sepsis as defined by the third international
consensus definitions for sepsis and septic shock [17]:
- Suspected infection
- SOFA score * 2

Exclusion Criteria

1) Patients who are moribund (not expected to be in ICU for more than 48 hours
due to imminent death)
2) A lack of commitment to full aggressive care during the first week due to
severity of illness, comorbidities and potential harm from maximal treatment
(anticipated withholding or withdrawing treatments in the first week)
3) Any trauma with severe injury or fracture of any extremity.
4) Rhabdomyolysis
5) Proven (pre-existing) skeletal muscle weakness (e.g. due to neuromuscular
disorders or immobility)
6) Renal dysfunction defined as a serum creatinine >171 *mol/L or a urine
output of less than 500 ml/last 24 hours
7) Patients requiring chronic veno-venous hemofiltration
8) Patients on any form of extracorporeal life support (ECMO/ELS)
9) Cirrhosis - Child*s class C liver disease
10) Metastatic cancer or Stage IV Lymphoma with life expectancy <6 months
11) Patients with primary admission diagnosis of burns (>30% body surface area)
12) Weight less than 50 kg or greater than 100 kg
13) Pregnant patients or lactating with the intent to breastfeed
14) Previous enrollment in this study
15) Previous participation in a 13C or 2H tracer study within the last year
16) Enrollment in any other interventional study

Study & Design

• Study Type: Interventional
• Study Design: Not specified